Related Experiment Video
Updated: Jan 29, 2026
Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
Published on: June 4, 2012
Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical
Alicia Galar1,2, Ana A Weil3,4, David M Dudzinski4,5
1Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain alg331@mail.harvard.edu.
Abstract:
Staphylococcus aureus prosthetic valve endocarditis (PVE) remains among the most morbid bacterial infections, with mortality estimates ranging from 40% to 80%. The proportion of PVE cases due to methicillin-resistant Staphylococcus aureus (MRSA) has grown in recent decades, to account for more than 15% of cases of S. aureus PVE and 6% of all cases of PVE. Because no large studies or clinical trials for PVE have been published, most guidelines on the diagnosis and management of MRSA PVE rely upon expert opinion and data from animal models or related conditions (e.g., coagulase-negative Staphylococcus infection). We performed a review of the literature on MRSA PVE to summarize data on pathogenic mechanisms and updates in epidemiology and therapeutic management and to inform diagnostic strategies and priority areas where additional clinical and laboratory data will be particularly useful to guide therapy. Major updates discussed in this review include novel diagnostics, indications for surgical management, the utility of aminoglycosides in medical therapy, and a review of newer antistaphylococcal agents used for the management of MRSA PVE.
Insights
Methicillin-resistant Staphylococcus aureus (MRSA) prosthetic valve endocarditis (PVE) is a severe infection with high mortality. This review updates on MRSA PVE epidemiology, diagnostics, and treatment strategies, including newer agents.
Area of Science:
- Infectious Diseases
- Cardiology
- Antimicrobial Resistance
Background:
- Prosthetic valve endocarditis (PVE) caused by Staphylococcus aureus has high mortality (40-80%).
- Methicillin-resistant Staphylococcus aureus (MRSA) accounts for over 15% of S. aureus PVE cases.
- Limited large studies necessitate reliance on expert opinion and related data for MRSA PVE management.
Purpose of the Study:
- To review the literature on MRSA PVE.
- To summarize pathogenic mechanisms, epidemiology, and therapeutic management updates.
- To inform diagnostic strategies and identify areas for future research.
Main Methods:
- Comprehensive literature review of MRSA PVE.
- Synthesis of data on disease mechanisms, epidemiology, and treatment.
- Analysis of novel diagnostics and therapeutic agents.
Main Results:
- MRSA PVE is an increasing concern with significant morbidity and mortality.
- Updates include novel diagnostic approaches and refined indications for surgical intervention.
- The role of aminoglycosides and newer antistaphylococcal agents in medical therapy is reviewed.
Conclusions:
- Effective management of MRSA PVE requires updated knowledge on diagnostics and therapeutics.
- Further clinical and laboratory research is crucial to optimize treatment strategies.
- This review provides a foundation for evidence-based clinical decision-making in MRSA PVE.
More Related Videos
Related Concept Videos
01:25Endocarditis II: Clinical Features of Infective Endocarditis
01:18Endocarditis III: Medical Management
01:29Endocarditis IV: Nursing Management
02:05Self-Presentation: Self-Monitoring and Self-Handicapping
01:22Mitral Valve Prolapse II: Assessment and Management
01:26Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations